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Objectives
A measure used for assessing the effectiveness of HIV care and comparing clinical centres is the
proportion of people starting antiretroviral therapy (ART) with viral suppression (VS) after 1 year. We
propose a method that adjusts for patients’ demographic characteristics, and visually compares this
measure between different sites accounting for centre size.
Methods
We analysed viral load measurements for UK Collaborative HIV Cohort (UK CHIC) patients starting ART
between 2006 and 2013. We used logistic regression to estimate the proportion with VS after 1 year of ART
adjusted for patient mix (in terms of age and a combined gender/ethnicity/acquisition mode variable) and
calendar year. We compared outcomes between centres using funnel plots which account for centre size.
Results
The overall proportion of the cohort with VS 1 year after starting ART was 90% and increased from
83% to 93% between 2006 and 2013. VS was lower in younger individuals. White men who have sex
with men (MSM) had the highest (94%), and black African (81%) and white (82%) heterosexual women
the lowest proportions achieving VS. Comparing the unadjusted funnel plot with the adjusted, there
were movements of some centres from outside to inside the 95% contour limits, which was largely
explained by the patient mix of these centres.
Conclusions
VS 1 year after ART start was associated with demographic characteristics and centre size; therefore, to
compare the performances of centres, adjustment for these factors is required. Adjusted funnel plot is an
effective tool which accounts for both the demographic characteristics and the centre size. Social factors,
rather than treatment decisions within the control of the centres, may drive differences in outcomes.
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Introduction
In health care settings, there is a need to assess services.
This is important in HIV services to obtain an overview
of the health of the community, for commissioning ser-
vices, and for monitoring of treatment outcomes.
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Measures should be carefully defined before being used
to monitor aspects of care. Understanding how patient
characteristics and centre size influence performance
measures is important for their effective use in monitor-
ing patient care in different settings.
In monitoring an HIV treatment programme, a number
of measures have been chosen [1–5]. A standard that is
often used is the proportion of people starting treatment
with antiretroviral therapy (ART) who have an unde-
tectable viral load (VL) 1 year after starting ART. The
proportion of people achieving an undetectable VL is an
important indicator of programme performance as it is a
marker of treatment adherence/success and has important
implications for reducing onward HIV transmission [6]
and for individual outcomes [7,8]. However, patient- as
well as provider-level factors are strongly associated with
the achievement of an undetectable VL, including mode
of HIV acquisition, age, gender and ethnicity [9,10]. As
the characteristics of those attending different centres
(the ‘case mix’) will vary, we need a tool that permits
researchers to illustrate and compare performance mea-
sures, such as the proportion of people with an unde-
tectable VL, after adjusting for any case-mix differences.
The aim of this study was to propose a methodology
for comparing HIV outcomes between centres, rather than
understanding the root causes of those differences, which
would require more detailed data on reasons for treat-
ment failure. We used data from the UK Collaborative
HIV Cohort (UK CHIC) study [11] to compare the propor-
tions of people with an undetectable VL at 1 year after
starting ART between UK HIV treatment centres. After
investigating differences in case mix between the centres,
we used funnel plots to describe the differences in this
performance measure between centres and to visually
illustrate the impact of case mix on the interpretation of
results from these analyses.
Methods
The UK CHIC study was initiated in 2001 and collates
routine data on HIV-positive individuals who have
attended a variety of clinical centres in the UK since 1
January 1996 (see Appendix 1). The project was approved
by a multi-centre research ethics committee. In accor-
dance with data protection policy, data were provided in
an anonymized format with any potential identifiers
removed. The criteria for inclusion of an individual in the
UK CHIC study are that they are HIV positive, have
attended one of the collaborating centres at any time
since 1996 and are aged ≥ 16 years. The present study
was conducted within the National Institute for Health
Research Health Protection Research Unit (NIHR HPRU) in
Blood Borne and Sexually Transmitted Infections (Univer-
sity College London in collaboration with the London
School of Hygiene and Tropical Medicine), and in Evalua-
tion of Interventions (University of Bristol) in partnership
with Public Health England (see Appendix 1).
In this study, eligible study participants were aged
≥ 20 years and started ART between 2006 and 2013. We
excluded from analyses people who transferred care or
died within 10 months of initiating ART and those who
did not have at least one VL recorded during that period.
Of the 19 eligible centres, data from two of them (labelled
as 6 and 13) were excluded for the year 2012 and data
from another one (labelled as 19) was included for the per-
iod 2009–2012 only, because of incomplete data in these
centres for the periods of exclusion. We calculated the
proportion of people with an undetectable VL at 1 year
after starting ART (defined in our primary analyses as
< 200 HIV-1 RNA copies/ml, but in sensitivity analyses as
< 50 copies/mL). We used the HIV-1 RNA measurement
that was recorded closest to 1 year after ART start, within
a window of up to 13 months after start of ART, in order
to allow for possible late recording of measurements. Peo-
ple whose only record was at ART start would be consid-
ered as not having suppressed VL at 1 year, if that
measurement was > 200 copies/mL (or 50 copies/mL).
We tabulated the proportion of people with an unde-
tectable VL by demographic characteristics and by calen-
dar year. As gender, ethnicity and mode of HIV
acquisition were highly correlated, we generated a com-
bined variable (gender/ethnicity/acquisition mode) for the
purposes of our analyses (with smaller categories com-
bined as ‘other’). We graphed the proportion of people
with undetectable VL by age, gender/ethnicity/acquisition
mode, and centre, and used logistic regression to estimate
the odds ratio (OR) for VL suppression by each factor.
Adjusting for case mix
We used logistic regression to model and predict the propor-
tion of individuals with viral suppression in each centre,
firstly unadjusted, and secondly adjusted for case mix (age
and gender/ethnic/acquisition mode). We fitted separate
models for each calendar year of ART initiation from 2006 to
2013 to account for the increasing trend in viral suppression
over the period of our study. We first estimated the unad-
justed and adjusted ORs of viral suppression at 1 year and
used these to predict the unadjusted and adjusted probabili-
ties of viral suppression for each person attending in that
year. For each centre, the “observed” proportions of people
with VL < 200 copies/mL were generated by computing the
average over all years of the unadjusted and adjusted proba-
bilities for people attending that centre.
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Funnel plots
We chose to use funnel plots to compare graphically the
unadjusted and adjusted measures as, by construction, they
account for the centre size. A funnel plot shows the scatter
of the observed measures for different centres compared to
the expected value which is the average of all centres. The
ratio of observed:expected measure is plotted against cen-
tre size. The contours representing the upper and lower
confidence interval for the expected proportion are wider
for small centres and narrower for large centres. The target
value of the ratio (observed:expected proportion) is 1 and
centres falling below the lower 95% contour limits are con-
sidered to have an observed proportion significantly lower
than expected (Fig. S1). A detailed explanation of how to
obtain adjusted funnel plots as used in this paper can be
found in Spiegelhalter and in Forni and Gini [12,13].
We constructed funnel plots for the ratio of the
observed:expected proportion of people with undetectable
VL plotted against centre size firstly using the unadjusted
data and secondly adjusting for case mix. For the unad-
justed funnel plot, we did not adjust for case mix, but did
account for changes in viral suppression over time in each
centre by taking the weighted average of the yearly pro-
portions, with weights equal to the number of people
attending that centre per year. For the adjusted funnel
plots, the ratio of the expected proportion after adjustment
to the observed proportion was calculated for each centre
and plotted against centre size. We graphed a histogram of
case mix by centre to inform the explanation of the move-
ment of the position of centres between the unadjusted
and adjusted funnel plots. In a sensitivity analysis, we con-
structed the funnel plots excluding the largest centre.
Results
The demographic characteristics of the 17 541 eligible
participants are presented in Table 1. In the cohort, 90%
of people overall achieved VL < 200 copies/mL 1 year
after starting ART and this proportion increased from
83% in 2006 to 93% in 2013 (Fig. 1). The corresponding
increase using the lower threshold for viral suppression
of < 50 copies/mL was from 74% in 2006 to 87% in
2013, with an average of 83% viral suppression overall
during this period. The proportion with undetectable VL
was lower for younger people, for women, and for those
Table 1 Percentage of people with viral suppression at 1 year after antiretroviral therapy (ART) start by demographic characteristics
Demographic variable Group Number in cohort Percentage in cohort VL < 200 copies/ml at 1 year (%)
Age 20–29 years 2984 17.01 85.16
30–39 years 6920 39.45 89.02
40–49 years 5349 30.49 92.56
> 50 years 2288 13.04 92.66
Gender Male (M) 12,828 73.13 92.98
Female (F) 4713 26.87 81.58
Ethnicity White (W) 9499 54.15 92.55
Black Caribbean 588 3.35 84.86
Black African (BA) 4918 28.04 84.99
Black unknown 426 2.43 84.04
Indian/Pakistani/Bangladeshi 271 1.54 92.25
Other Asian 401 2.29 93.27
Other mixed (OM) 753 4.29 92.70
Other (O) 331 1.89 92.15
Unknown (U) 354 2.02 89.55
Acquisition mode MSM 8955 51.05 94.21
Injecting drug users 329 1.88 76.90
Heterosexuals (HS) 6909 39.39 85.37
Other (O) 116 0.66 86.21
Unknown (U) 1232 7.02 88.07
Gender/ethnicity/acquisition mode* M/W/MSM 7310 41.67 94.20
F/BA/HS 2984 17.01 81.43
M/BA/HS 1463 8.34 91.52
M/W/HS 655 3.73 91.76
M/W/U 632 3.60 90.82
F/W/HS 533 3.04 82.18
M/OM/MSM 442 2.52 96.38
Other 3522 20.08 87.39
*Groups of the gender/ethnicity/acquisition mode variable are: white MSM (M/W/MSM), black African heterosexual women (F/BA/HS), black African
heterosexual men (M/BA/HS), white heterosexual men (M/W/HS), white men of unknown acquisition mode (M/W/U), white heterosexual women (F/W/
HS), and MSM of other mixed ethnicity (M/OM/MSM). All other combinations are included in the ‘Other’ group.
MSM, men who have sex with men; VL, viral load.
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with black African or black Caribbean ethnicity. Men
who have sex with men (MSM) had the highest, and peo-
ple who inject drugs (PWID) the lowest, rates of viral
suppression (Table 1).
The proportion of people with viral suppression at
1 year increased with age (Fig. 2a). There were significant
differences in viral suppression between HIV acquisition
mode groups (Fig. 2b). In particular, white MSM had a
higher proportion (94%) achieving VL < 200 copies/mL
compared with other large groups, while the lowest pro-
portions were observed for black African and white
heterosexual women (81% and 82%, respectively). The
proportion of people achieving viral suppression
increased over calendar year for all age groups (Fig. 2c)
and for all categories of patients (Fig. 2d).
Centres with more patients tended to have a higher
proportion of people who achieved viral suppression; fur-
thermore, sampling variability was greater for smaller
centres, as shown by the wider confidence intervals
around this proportion (Fig. 3).
Effects of adjustment for case mix
Table 2 compares the observed proportion of people with
viral suppression for each centre with the expected pro-
portions before and after adjustment for case mix. Com-
pared to the unadjusted proportion, the adjusted expected
proportion with viral suppression is closer to the observed
proportion for most of the centres (highlighted with grey
colour in the table).
The results for all UK CHIC centres included in our
analysis are illustrated in the funnel plots (Fig. 4). In the
unadjusted case, centres 5, 14 and 18 have lower than
expected proportions of people with viral suppression
(falling below or exactly on the 95% lower contour).
However, after adjustment, these centres move inside the
95% contour limits. In contrast, while centre 3 seemed to
do a lot better than expected prior to adjustment, it
moved within the expected range after adjustment.
Fig. 1 Trend in proportion of people with VL< 50 and < 200 copies/
ml at 1 year after start of ART.
Fig. 2 Proportion (with 95% CI) of eligible participants with VL < 200 copies/mL at 1 year by age group (left) and by sex/ethnicity/acquisition
mode group (right). Upper panels show overall proportion suppressed with 95% confidence intervals and lower panels show trends over time.
© 2018 The Authors.
HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association
HIV Medicine (2018), 19, 386--394
Funnel plots to compare HIV centres: UK CHIC 389
The case mix of attendees varied by centre (Fig. 5).
For example, centre 3 had a high proportion of white
MSM, a group that is more likely to have a suppressed
VL after 1 year compared with other groups, and low
proportions of black African and white women, groups
that tend to be less likely to have viral suppression. The
opposite situation occurred with centres 5, 14 and 18,
which had high proportions of groups that were less
likely to have undetectable VL (i.e. black African
women, white men with unknown mode of HIV acquisi-
tion and those with an ‘other’ mode of acquisition).
These observations explain the movement of the points
in the adjusted compared with the unadjusted funnel
plots (circled points in Fig. 4). As centre 3 had many
more attendees than the other centres and had the high-
est proportion of people with undetectable VL, it had a
strong influence on the shape of the funnel plots,
extending them to the right, and made a large contribu-
tion to the estimate of the average, that is, the position
of the horizontal line representing a ratio of 1. When we
excluded centre 3, centres 5 and 14 fell well inside the
contour limits and only centre 18 remained outside the
95% contour lines in the unadjusted funnel plot
(Fig. S2). On adjustment, centre 18 moved well inside
Fig. 3 Proportion of people with VL < 200 copies/mL at 1 year by centre (left) and by number of eligible participants (centre size) (right).
Table 2 Difference between unadjusted and risk-adjusted proportions of people with viral suppression
Centre label Number of eligible participants Observed proportion (%) Unadjusted expected proportion (%) Adjusted expected proportion (%)
1 1004 90.84 89.87 92.42
2 1432 92.67 89.91 91.23
3 4213 94.49 90.41 92.47
4 1920 91.77 89.68 91.13
5 1449 85.02 89.72 87.47
6* 1193 89.10 89.10 89.54
7 1299 87.61 89.90 90.05
8 338 88.17 89.60 88.28
9 578 82.70 89.61 85.97
10 543 87.66 90.20 86.83
11 625 90.72 89.83 89.22
12 721 90.43 89.44 86.58
13* 188 92.55 89.84 88.67
14 630 83.02 90.05 86.34
15 283 87.63 90.62 87.27
16 214 82.71 89.90 87.18
17 107 85.05 91.33 88.26
18 486 79.63 89.48 87.12
19* 318 89.94 89.87 86.65
Highlighted (light grey) centres are those whose case-mix adjusted proportion was closer to the observed value compared to the unadjusted propor-
tion.
*Centres with missing data for some periods between 2006 and 2013.
© 2018 The Authors.
HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association
HIV Medicine (2018), 19, 386--394
390 M Gompels et al.
the funnel, indicating that the proportion of people with
viral suppression was as expected.
Discussion
Our study shows that funnel plots used in conjunction
with regression modelling are a useful tool for monitor-
ing centre performance for an important clinical outcome
in a fair way that accounts for centre size and case mix.
In this application, we have investigated differences
between HIV treatment centres in the proportion of HIV-
positive people that have undetectable VL 1 year after
starting ART. The funnel shape of the 95% confidence
interval contours correctly allows for the greater sam-
pling variation that occurs in smaller centres. The plots
also provide a benchmark of the expected performance
that is based on an average over all centres.
Our data clearly showed that the likelihood of having
undetectable VL at 1 year after ART start was associated
with individual characteristics. Furthermore, we showed
that case mix was very variable between centres, with
some treating mostly MSM and others treating mostly
those infected via non-MSM routes. While in the unad-
justed funnel plots some of the centres were outside the
expected 95% confidence limits, adjusting for case mix
resulted in all centres being within the confidence limits
on the funnel plots. The generation of funnel plots using
the methodology described provides an objective way of
comparing different centres with different case mixes.
The data on VL show that for the UK CHIC population
there is an impact on viral suppression of age at start of
treatment and sex/ethnic/acquisition mode group.
Younger people are less likely to have undetectable VL
than older people. Viral suppression is also more likely in
MSM than in heterosexuals, in men than in women, and
in white people compared with those of black African
ethnicity. While these are not new findings [14], what we
Fig. 4 Unadjusted (left) and adjusted (right) funnel plots showing ratio of observed to expected proportion of people with undetectable viral
load (VL) vs. size of centre.
Fig. 5 Stacked bar chart showing variation in case-mix (gender/eth-
nicity/acquisition mode) between centres.
© 2018 The Authors.
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have done is use this information to standardize the pop-
ulation. The adjustments of the data to account for the
variations in patient characteristics indicated that centres
that were outside the 95% confidence limit all became
acceptable performers. Similarly, centres near the bound-
ary became closer to the expected value. In contrast, cen-
tre 3, which was the largest centre, treated mostly MSM
and had a much higher than expected proportion of peo-
ple with undetectable VL in unadjusted analysis, became
closer to the expected value after adjustment for case
mix. This shows how important the case mix is in deter-
mining a centre’s assessed ‘ability’ to achieve viral sup-
pression in its local population.
Limitations
While UK CHIC includes a good geographical representa-
tion of the UK epidemic, it is not fully national (with
around 40% coverage). Previous work has shown that it
is a representative sample of people receiving treatment
for HIV infection in the UK [15]. Funnel plots may be
biased by the inclusion of data from very large centres.
Because large centres contribute most to the calculation
of the mean used for benchmarking, they may skew the
data and bias the funnel plot. This will happen if large
centres are unrepresentative, as is the case here where the
largest centre was treating mostly MSM and had the
highest proportion of people with an undetectable VL.
The benchmarking line was biased upward and other cen-
tres were therefore more likely to fall below the lower
95% confidence interval. Therefore, large centres can
exert undue influence on the funnel plot. If standards for
commissioning are based on how the largest centres
which cater mostly for MSM are performing, then other
centres may appear to be falling behind. However, we
investigated this by re-running the funnel plots excluding
centre 3.
There are a number of other limitations in our analysis
of VL. We did not account for frequency of VL testing,
VL assay, or presence of resistance in our model, which
may have varied by centre and therefore affected our
results. We hypothesized that VL measurements might be
more frequent in those whose VL declined more slowly.
However, we found that VL measurements were less fre-
quent in those with unsuppressed VL at 1 year. We could
only adjust for differences in a few key patient demo-
graphics, but this only partially captures the true case
mix of individuals attending different centres. Other
social factors not measured in our study, such as migra-
tion status, poverty, social support, and mental health,
may affect individuals’ ability to adhere to ART. It is
perhaps remarkable that the observed centre variation has
been explained adequately, that is, within the statistical
limits that might indicate it is attributable to chance, only
by demographic case mix. Of course, we are only analys-
ing the outcomes of people who start ART and who are
monitored – clearly, some of the patients may never start
ART, or may not regularly attend centres to have their
VL measured. In our analysis, we did not include individ-
uals who transferred their care in the first 10 months
after starting ART or who died as they could not con-
tribute to the assessment of VL at 1 year. However, we
did include individuals who may have stopped ART
before 1 year. Therefore we are analysing the effective-
ness of HIV care rather than the efficacy of ART. The
proportion of patients with suppressed virus would have
been higher if we had restricted analyses to those who
remained on and adherent to ART at 1 year. We do not
know the reasons for lack of viral suppression, nor
whether these varied by demographic group. For exam-
ple, there may be some women who started ART in preg-
nancy to prevent mother-to-child transmission who did
not continue treatment after delivery, although guidelines
since 2010 have recommended lifelong ART for the
mother’s own health needs.
There is a considerable focus on the cascade of care in
monitoring the HIV epidemic, with a goal to achieve
90:90:90, that is 90% of those with HIV diagnosed, 90%
of those diagnosed on treatment, and 90% of treated
patients achieving undetectable VL [16]. When population
targets are based on a set level then it does not matter
what the case mix is when you are considering whether
countries or centres have met the target. However, adjust-
ment for case mix and consideration of centre size is
important when direct comparisons are made between
centres and any differences are attributed to inadequacies
in the care that is provided. Our study demonstrates how
illustrative it is to use the funnel plot as a method.
Comparisons made in this way, are very helpful to those
providing services, as a benchmark, and those commis-
sioning, as an accurate performance measure.
Conclusions
Funnel plots accounting for expected variability attribu-
table to centre size and adjusting for case mix are useful
tools for monitoring performance in HIV treatment cen-
tres and for assessing comparative progress in a fair man-
ner at the local level.
In this UK-based study, there was a significant impact
of age, sex, ethnicity and mode of HIV acquisition group
on the proportion of people with undetectable VL 1 year
© 2018 The Authors.
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after starting ART. Adjustment by these variables chan-
ged the relative positions of some of the centres in the
funnel plot. Those centres that had higher or lower
observed compared to expected proportion of patients
with undetectable VL were no longer outside the 95%
contour line in the adjusted funnel plot. Moreover, sup-
pression of VL seemed to be lower at smaller centres, but
the use of the adjusted funnel plot suggested that all of
them fell within the expected region defined by the 95%
contour limits. Our findings suggest that differences in
outcomes of care between HIV centres are more likely to
be attributable to patient case mix, which depends on
geographical location and social factors, rather than
treatment decisions within the control of clinicians.
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Additional Supporting Information may be found in the
online version of this article at the publisher’s web-site:
Fig. S1 Showing the construction and interpretation of a
Funnel plot.
Fig. S2 For comparison with Fig. 4 - Unadjusted (left)
and adjusted (right) funnel plots showing ratio of
observed to expected proportion of people with unde-
tectable viral load (VL) vs. size of centre omitting the lar-
gest centre (centre 3).
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Table S1. Showing the demographic distribution of the
excluded cases (transferred care and no VL measurement
within 10 months).
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